Ravali Tarigopula, MD
Pulmonary Disease · Starkville, MSNPI 1285802892
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 268 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by GSK at 35.9% of the total. That places this record below the midpoint for pulmonary disease clinicians in MS, where the typical reported total is $4,861.
Across 268 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$848
- Boehringer Ingelheim$518
- Sunovion Pharmaceuticals Inc.$328
- Sanofi$160
- Mylan Specialty L.p.$133
- plus $1K from 25 others
What the payments were for
- Consulting fees$501%
- Food & beverage$4,69599%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 109 | $1,709 |
| AstraZeneca(2 entities) | 45 | $848 |
| Boehringer Ingelheim | 25 | $518 |
| Sunovion Pharmaceuticals Inc. | 25 | $328 |
| Sanofi | 8 | $160 |
| Mylan Specialty L.p. | 7 | $133 |
| Baxter Healthcare | 5 | $124 |
| Grifols USA, LLC | 5 | $107 |
| United Therapeutics Corporation | 4 | $95 |
| Harmony Biosciences LLC | 3 | $66 |
| Jazz Pharmaceuticals Inc. | 3 | $65 |
| Abiomed | 2 | $54 |
| Pfizer | 2 | $49 |
| Resmed Corp | 2 | $48 |
| Merck | 2 | $43 |
| Insmed, Inc. | 2 | $43 |
| Philips North America LLC | 3 | $41 |
| Verona Pharma, Inc. | 2 | $39 |
| Advanced Respiratory, Inc | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Chiesi USA, Inc. | 1 | $25 |
| Viatris Specialty LLC | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Amgen | 1 | $21 |
| Pulmonx Corporation | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Bayer | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
How this compares
$4,756 in reported general payments places this provider in the 45th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 311 | $232,081 |
| OfevNintedanib Esylate | 12 | $157,820 |
| Dupixent SyringeDupilumab | 24 | $98,789 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 103 | $86,088 |
| Breo ElliptaFluticasone/Vilanterol | 145 | $63,167 |
| Spiriva RespimatTiotropium Bromide | 42 | $30,093 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $22,143 |
| SymbicortBudesonide/Formoterol Fumarate | 69 | $20,643 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 35 | $17,206 |
| Incruse ElliptaUmeclidinium Bromide | 43 | $16,078 |
| Spiriva HandihalerTiotropium Bromide | 24 | $12,087 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 45 | $7,880 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 20 | $7,814 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 413 | $7,770 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 80 | $7,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,709 | $333,469543 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $518 | $205,11989 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $848 | $114,545192 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Starkville
- Cameron HuxfordStarkville$155K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
- Bobby TullosGulfport$276K
- Michal SenitkoJackson$185K
- L AldredHattiesburg$76K
- Andrew WilhelmJackson$51K
- Raymond PortisJackson$39K
- Jaime UngoTupelo$29K
- Olukunle AjagbeMcComb$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.